Tuberculosis Tb Diagnostics Market
Tuberculosis (TB) Diagnostics Market Forecasts to 2028 - Global Analysis by Product Types (Detection of Latent Infection, Cytokine Detection Assay, Diagnostic Laboratory Methods, Other Product Types), Test Type (Tuberculin skin tests, Interferon-gamma release assays (IGRAs), Smear microscopy, Other test types), Type (Sputum Smear Microscopy, Rapid Molecular Diagnostics, Other Types), End-user (Diagnostic Laboratories, Hospitals, Other end users), and By Geography
Years Covered |
2020-2028 |
Estimated Year Value (2022) |
US $1.84 BN |
Projected Year Value (2028) |
US $2.94 BN |
CAGR (2022 - 2028) |
8.1% |
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
Largest Market |
North America |
Fastest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Tuberculosis (TB) Diagnostics Market is accounted for $1.84 billion in 2022 and is expected to reach $2.94 billion by 2028 growing at a CAGR of 8.1% during the forecast period. Mycobacterium tuberculosis is a type of bacteria that causes the dangerous disease tuberculosis. The patient's lungs are typically the target of the illness. The infection can also affect the spine and the brain, among other bodily parts. Skin testing and blood tests can be used to diagnose tuberculosis. The necessity for precise and effective diagnostic tests to stop the spread of this condition has increased as its incidence has increased. In the upcoming years, it is anticipated that this factor will dramatically increase demand for tuberculosis tests.
According to the Global Tuberculosis Report 2021 published by the World Health Organization, in October 2021, most of the tuberculosis cases were found in the World Health Organization (WHO) regions of South-East Asia (43%), Africa (25%), and the Western Pacific (18%), and lesser numbers of tuberculosis cases were found in Eastern Mediterranean (8.3%), and Europe (2.3%). According to the data published by the World Health Organization (WHO), in October 2021, about 1.5 million people worldwide died because of tuberculosis (TB), in 2020, and approximately 10 million people fell ill with tuberculosis globally.
Market Dynamics:
Driver:
Favourable Government Policies to Surge the Demand
To lessen the global burden of tuberculosis, governments have strengthened their policies for diagnosis. Over the coming years, there will likely be a rise in the need for diagnoses as awareness of the disease's seriousness grows across all nations. The creation of measures to boost tuberculosis diagnosis rates has received emphasis in several nations. The need for government policies and laws to raise tuberculosis diagnosis rates is further increased by factors such the high prevalence of tuberculosis in countries with large burdens of the disease and the rising demand for TB testing. Additionally, it is anticipated that in the near future, sales of TB diagnostics would increase significantly due to growing awareness in high-TB burden nations where the main goal is to reduce tuberculosis cases.
Restraint:
Limitations of Existing Tuberculosis (TB) Diagnostics
Despite the urgent and growing need for better diagnostics for various diseases, there are a few obstacles that could prevent the market from expanding throughout the projected period. For instance, during the projected period, some technical challenges related to tuberculosis diagnostics may significantly constrain the market. One of the main factors preventing the market from expanding more broadly is the greater level of technical difficulties in establishing these diagnostic technologies.
Opportunity:
Rising Incidence of Tuberculosis in High Burden Countries
The huge rise in this disease's occurrence in emerging nations is one of the most important factors that is positively affecting the market's expansion. For instance, the number of patients with tuberculosis has increased significantly during the past few decades. In order to improve patient outcomes and boost the precision of these diagnoses, this element generated demand for research into efficient diagnostic technology.
Threat:
High costs associated with tuberculosis diagnostics
Some of the challenges impeding market expansion during the projection period include the high costs associated with tuberculosis tests and the lack of insurance coverage in emerging markets. Patients may incur catastrophic costs as a result of their TB. For patients, income loss frequently represents the biggest financial risk. TB patients and their families need to get appropriate income replacement and other social protection interventions, in addition to making sure that healthcare services are equitably funded and provided in a way that reduces direct and indirect expenses.
Covid-19 Impact:
During the COVID-19 pandemic, there was a decrease in the need for tuberculosis diagnostic products. This element was brought on by the sharp fall in the number of patients diagnosed with TB. Compared to the previous year, the growth of the global market shrank. The incidence of TB testing decreased in the high-burden areas of the worldwide market as a result of the COVID-19 pandemic. Despite the disease's high level of infectiousness, during the early stages of the pandemic, funding for initiatives to diagnose tuberculosis was diverted to combat the coronavirus pandemic.
The rapid molecular diagnostics is expected to be the largest during the forecast period
During the projection period, new product launches in the rapid molecular diagnostics market are also predicted to further fuel the segment's expansion. The market leader and predicted to continue to have a sizeable market share is the rapid molecular diagnostics sector. Rapid molecular diagnostics for TB detection are credited with the efficiency and accuracy that have led to the segment's rise. Rapid molecular diagnostics for TB detection are credited with the efficiency and accuracy that have led to the segment's rise.
The diagnostic laboratories segment is expected to have the highest CAGR during the forecast period
The market is divided into diagnostic laboratories and hospitals based on the end user. During the forecast period, the market's highest CAGR growth rate was accounted for by the diagnostic laboratories sector. The category is expanding as a result of the widespread use of diagnostic laboratories. The category is expanding as a result of an uptick in the number of TB diagnoses performed in these diagnostic labs. The category is expanding as a result of an uptick in the number of TB diagnoses performed in these diagnostic labs.
Region with highest share:
Due to factors including the rising tuberculosis incidence in the region, the presence of a well-established healthcare infrastructure, and high healthcare spending, North America is predicted to hold largest share in the tuberculosis diagnostic market. The primary reason fueling the market's expansion is the increased prevalence of tuberculosis in the area. Additionally, it is anticipated that the company's efforts to produce cutting-edge medicines would increase in response to the region's rising healthcare spending, fueling the market's expansion.
Region with highest CAGR:
During the forecast period, the market in Asia Pacific is anticipated to experience a high CAGR. The Asia Pacific market is growing at a faster rate than other regions due to improvements in healthcare infrastructure, a high prevalence of TB disease, and rising consumer desire for better treatment outcomes.
Key players in the market
Some of the key players in Tuberculosis (TB) Diagnostics market include Becton, Dickinson and Company, Abbott Laboratories, Siemens, Hologic Corporation, Cepheid, BioMérieux SA, Hain Life sciences GmBH, F.Hoffmann-La Roche AG, Alere, Inc., F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN (Netherlands), Hain Life science GmbH, Oxford Immunotec USA, Inc., Akonni Biosystems, Inc., Epistem Ltd., Johnson & Johnson Services, Inc., Novartis AG, GlaxoSmithKline PLC, PerkinElmer Inc.
Key Developments:
In May 2022, F. Hoffmann-La Roche Ltd entered into a partnership with the Global Fund to support low and middle-income countries in strengthening critical diagnosis infrastructure against infectious diseases.
In March 2022, Thermo Fisher Scientific Inc. launched the SeqStudio Flex Series Genetic Analyzer for research and development of infectious disease detection, which is expected to expand the company's product portfolio in the market.
In February 2022, QIAGEN announced that its Quanti FERON tuberculosis testing solution received the approval of the fourth generation of a modern gold standard test in China.
In July 2021, F. Hoffmann-La Roche Ltd. announced that WHO included the company’s products cobas MTB and cobas MTB-RIF/INH tests as Nucleic Acid Amplification Tests Go (NAATs). These products are nucleic acid testing products used to detect tuberculosis and drug resistance TB.
In March 2021, Hologic, Inc. announced the CE marking of its tuberculosis (TB) IGRA test on VIDAS. VIDAS TB-IGRA is an automated assay that helps in the diagnosis of infection with Mycobacterium tuberculosis.
Products Covered:
• Detection of Latent Infection
• Cytokine Detection Assay
• Diagnostic Laboratory Methods
• Nucleic Acid Testing
• Detection of Drug Resistance
• Radiographic Method
• Other Product Types
Test Types Covered:
• Wet Tuberculin skin tests
• Interferon-gamma release assays (IGRAs)
• Smear microscopy
• Serological antibody-based tests
• Culture
• Identification or speciation tests
• Nucleic acid amplification tests (NAATs)
• Phenotypic drug susceptibility tests
• Adenosine deaminase (ADA) test.
Types Covered:
• Sputum Smear Microscopy
• Rapid Molecular Diagnostics
• Culture-based Diagnostics
• Other Types
End Users Covered:
• Diagnostic Laboratories
• Hospitals
• Clinics
• Reference Laboratories
• Research Institutes and Academics
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Tuberculosis (TB) Diagnostics Market, By Product
5.1 Introduction
5.2 Detection of Latent Infection
5.3 Cytokine Detection Assay
5.4 Diagnostic Laboratory Methods
5.5 Nucleic Acid Testing
5.6 Detection of Drug Resistance
5.7 Radiographic Method
5.8 Other Products
6 Global Tuberculosis (TB) Diagnostics Market, By Test Type
6.1 Introduction
6.2 Tuberculin Skin Tests
6.3 Interferon-Gamma Release Assays (IGRAs)
6.4 Smear Microscopy
6.5 Serological Antibody-Based Tests
6.6 Culture
6.7 Identification or Speciation Tests
6.8 Nucleic Acid Amplification Tests (NAATs)
6.9 Phenotypic Drug Susceptibility Tests
6.10 Adenosine Deaminase (ADA) Test
7 Global Tuberculosis (TB) Diagnostics Market, By Type
7.1 Introduction
7.2 Sputum Smear Microscopy
7.3 Rapid Molecular Diagnostics
7.4 Culture-based Diagnostics
7.5 Other Types
8 Global Tuberculosis (TB) Diagnostics Market, By End User
8.1 Introduction
8.2 Diagnostic Laboratories
8.3 Hospitals
8.3.1 Public
8.3.2 Private
8.4 Clinics
8.5 Reference Laboratories
8.6 Research Institutes and Academics
8.7 Other End Users
9 Global Tuberculosis (TB) Diagnostics Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Becton, Dickinson and Company
11.2 Abbott Laboratories
11.3 Siemens
11.4 Hologic Corporation
11.5 Cepheid
11.6 bioMérieux SA
11.7 Hain Lifesciences GmBH
11.8 F.Hoffmann-La Roche AG
11.9 Alere, Inc.
11.10 F. Hoffmann-La Roche Ltd (Switzerland)
11.11 Thermo Fisher Scientific Inc. (U.S.)
11.12 QIAGEN (Netherlands)
11.13 Hain Lifescience GmbH
11.14 Oxford Immunotec USA, Inc.
11.15 Akonni Biosystems, Inc.
11.16 EpistemLtd.
11.17 Johnson & Johnson Services, Inc.
11.18 Novartis AG
11.19 GlaxoSmithKline PLC
11.20 PerkinElmer Inc.
List of Tables
1 Global Tuberculosis (TB) Diagnostics Market Outlook, By Region (2020-2028) ($MN)
2 Global Tuberculosis (TB) Diagnostics Market Outlook, By Product Types (2020-2028) ($MN)
3 Global Tuberculosis (TB) Diagnostics Market Outlook, By Detection of Latent Infection (2020-2028) ($MN)
4 Global Tuberculosis (TB) Diagnostics Market Outlook, By Cytokine Detection Assay (2020-2028) ($MN)
5 Global Tuberculosis (TB) Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2020-2028) ($MN)
6 Global Tuberculosis (TB) Diagnostics Market Outlook, By Nucleic Acid Testing (2020-2028) ($MN)
7 Global Tuberculosis (TB) Diagnostics Market Outlook, By Detection of Drug Resistance (2020-2028) ($MN)
8 Global Tuberculosis (TB) Diagnostics Market Outlook, By Radiographic Method (2020-2028) ($MN)
9 Global Tuberculosis (TB) Diagnostics Market Outlook, By Other Products (2020-2028) ($MN)
10 Global Tuberculosis (TB) Diagnostics Market Outlook, By Test Type (2020-2028) ($MN)
11 Global Tuberculosis (TB) Diagnostics Market Outlook, By Tuberculin Skin Tests (2020-2028) ($MN)
12 Global Tuberculosis (TB) Diagnostics Market Outlook, By Interferon-Gamma Release Assays (IGRAs) (2020-2028) ($MN)
13 Global Tuberculosis (TB) Diagnostics Market Outlook, By Smear Microscopy (2020-2028) ($MN)
14 Global Tuberculosis (TB) Diagnostics Market Outlook, By Serological Antibody-Based Tests (2020-2028) ($MN)
15 Global Tuberculosis (TB) Diagnostics Market Outlook, By Culture (2020-2028) ($MN)
16 Global Tuberculosis (TB) Diagnostics Market Outlook, By Identification or Speciation Tests (2020-2028) ($MN)
17 Global Tuberculosis (TB) Diagnostics Market Outlook, By Nucleic Acid Amplification Tests (NAATs) (2020-2028) ($MN)
18 Global Tuberculosis (TB) Diagnostics Market Outlook, By Phenotypic Drug Susceptibility Tests (2020-2028) ($MN)
19 Global Tuberculosis (TB) Diagnostics Market Outlook, By Adenosine Deaminase (ADA) Test (2020-2028) ($MN)
20 Global Tuberculosis (TB) Diagnostics Market Outlook, By Type (2020-2028) ($MN)
21 Global Tuberculosis (TB) Diagnostics Market Outlook, By Sputum Smear Microscopy (2020-2028) ($MN)
22 Global Tuberculosis (TB) Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2020-2028) ($MN)
23 Global Tuberculosis (TB) Diagnostics Market Outlook, By Culture-based Diagnostics (2020-2028) ($MN)
24 Global Tuberculosis (TB) Diagnostics Market Outlook, By Other Types (2020-2028) ($MN)
25 Global Tuberculosis (TB) Diagnostics Market Outlook, By End User (2020-2028) ($MN)
26 Global Tuberculosis (TB) Diagnostics Market Outlook, By Diagnostic Laboratories (2020-2028) ($MN)
27 Global Tuberculosis (TB) Diagnostics Market Outlook, By Hospitals (2020-2028) ($MN)
28 Global Tuberculosis (TB) Diagnostics Market Outlook, By Public (2020-2028) ($MN)
29 Global Tuberculosis (TB) Diagnostics Market Outlook, By Private (2020-2028) ($MN)
30 Global Tuberculosis (TB) Diagnostics Market Outlook, By Clinics (2020-2028) ($MN)
31 Global Tuberculosis (TB) Diagnostics Market Outlook, By Reference Laboratories (2020-2028) ($MN)
32 Global Tuberculosis (TB) Diagnostics Market Outlook, By Research Institutes and Academics (2020-2028) ($MN)
33 Global Tuberculosis (TB) Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
34 North America Tuberculosis (TB) Diagnostics Market Outlook, By Country (2020-2028) ($MN)
35 North America Tuberculosis (TB) Diagnostics Market Outlook, By Product Types (2020-2028) ($MN)
36 North America Tuberculosis (TB) Diagnostics Market Outlook, By Detection of Latent Infection (2020-2028) ($MN)
37 North America Tuberculosis (TB) Diagnostics Market Outlook, By Cytokine Detection Assay (2020-2028) ($MN)
38 North America Tuberculosis (TB) Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2020-2028) ($MN)
39 North America Tuberculosis (TB) Diagnostics Market Outlook, By Nucleic Acid Testing (2020-2028) ($MN)
40 North America Tuberculosis (TB) Diagnostics Market Outlook, By Detection of Drug Resistance (2020-2028) ($MN)
41 North America Tuberculosis (TB) Diagnostics Market Outlook, By Radiographic Method (2020-2028) ($MN)
42 North America Tuberculosis (TB) Diagnostics Market Outlook, By Other Products (2020-2028) ($MN)
43 North America Tuberculosis (TB) Diagnostics Market Outlook, By Test Type (2020-2028) ($MN)
44 North America Tuberculosis (TB) Diagnostics Market Outlook, By Tuberculin Skin Tests (2020-2028) ($MN)
45 North America Tuberculosis (TB) Diagnostics Market Outlook, By Interferon-Gamma Release Assays (IGRAs) (2020-2028) ($MN)
46 North America Tuberculosis (TB) Diagnostics Market Outlook, By Smear Microscopy (2020-2028) ($MN)
47 North America Tuberculosis (TB) Diagnostics Market Outlook, By Serological Antibody-Based Tests (2020-2028) ($MN)
48 North America Tuberculosis (TB) Diagnostics Market Outlook, By Culture (2020-2028) ($MN)
49 North America Tuberculosis (TB) Diagnostics Market Outlook, By Identification or Speciation Tests (2020-2028) ($MN)
50 North America Tuberculosis (TB) Diagnostics Market Outlook, By Nucleic Acid Amplification Tests (NAATs) (2020-2028) ($MN)
51 North America Tuberculosis (TB) Diagnostics Market Outlook, By Phenotypic Drug Susceptibility Tests (2020-2028) ($MN)
52 North America Tuberculosis (TB) Diagnostics Market Outlook, By Adenosine Deaminase (ADA) Test (2020-2028) ($MN)
53 North America Tuberculosis (TB) Diagnostics Market Outlook, By Type (2020-2028) ($MN)
54 North America Tuberculosis (TB) Diagnostics Market Outlook, By Sputum Smear Microscopy (2020-2028) ($MN)
55 North America Tuberculosis (TB) Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2020-2028) ($MN)
56 North America Tuberculosis (TB) Diagnostics Market Outlook, By Culture-based Diagnostics (2020-2028) ($MN)
57 North America Tuberculosis (TB) Diagnostics Market Outlook, By Other Types (2020-2028) ($MN)
58 North America Tuberculosis (TB) Diagnostics Market Outlook, By End User (2020-2028) ($MN)
59 North America Tuberculosis (TB) Diagnostics Market Outlook, By Diagnostic Laboratories (2020-2028) ($MN)
60 North America Tuberculosis (TB) Diagnostics Market Outlook, By Hospitals (2020-2028) ($MN)
61 North America Tuberculosis (TB) Diagnostics Market Outlook, By Public (2020-2028) ($MN)
62 North America Tuberculosis (TB) Diagnostics Market Outlook, By Private (2020-2028) ($MN)
63 North America Tuberculosis (TB) Diagnostics Market Outlook, By Clinics (2020-2028) ($MN)
64 North America Tuberculosis (TB) Diagnostics Market Outlook, By Reference Laboratories (2020-2028) ($MN)
65 North America Tuberculosis (TB) Diagnostics Market Outlook, By Research Institutes and Academics (2020-2028) ($MN)
66 North America Tuberculosis (TB) Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
67 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Country (2020-2028) ($MN)
68 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Product Types (2020-2028) ($MN)
69 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Detection of Latent Infection (2020-2028) ($MN)
70 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Cytokine Detection Assay (2020-2028) ($MN)
71 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2020-2028) ($MN)
72 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Nucleic Acid Testing (2020-2028) ($MN)
73 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Detection of Drug Resistance (2020-2028) ($MN)
74 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Radiographic Method (2020-2028) ($MN)
75 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Other Products (2020-2028) ($MN)
76 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Test Type (2020-2028) ($MN)
77 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Tuberculin Skin Tests (2020-2028) ($MN)
78 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Interferon-Gamma Release Assays (IGRAs) (2020-2028) ($MN)
79 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Smear Microscopy (2020-2028) ($MN)
80 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Serological Antibody-Based Tests (2020-2028) ($MN)
81 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Culture (2020-2028) ($MN)
82 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Identification or Speciation Tests (2020-2028) ($MN)
83 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Nucleic Acid Amplification Tests (NAATs) (2020-2028) ($MN)
84 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Phenotypic Drug Susceptibility Tests (2020-2028) ($MN)
85 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Adenosine Deaminase (ADA) Test (2020-2028) ($MN)
86 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Type (2020-2028) ($MN)
87 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Sputum Smear Microscopy (2020-2028) ($MN)
88 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2020-2028) ($MN)
89 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Culture-based Diagnostics (2020-2028) ($MN)
90 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Other Types (2020-2028) ($MN)
91 Europe Tuberculosis (TB) Diagnostics Market Outlook, By End User (2020-2028) ($MN)
92 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Diagnostic Laboratories (2020-2028) ($MN)
93 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Hospitals (2020-2028) ($MN)
94 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Public (2020-2028) ($MN)
95 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Private (2020-2028) ($MN)
96 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Clinics (2020-2028) ($MN)
97 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Reference Laboratories (2020-2028) ($MN)
98 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Research Institutes and Academics (2020-2028) ($MN)
99 Europe Tuberculosis (TB) Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
100 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Country (2020-2028) ($MN)
101 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Product Types (2020-2028) ($MN)
102 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Detection of Latent Infection (2020-2028) ($MN)
103 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Cytokine Detection Assay (2020-2028) ($MN)
104 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2020-2028) ($MN)
105 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Nucleic Acid Testing (2020-2028) ($MN)
106 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Detection of Drug Resistance (2020-2028) ($MN)
107 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Radiographic Method (2020-2028) ($MN)
108 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Other Products (2020-2028) ($MN)
109 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Test Type (2020-2028) ($MN)
110 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Tuberculin Skin Tests (2020-2028) ($MN)
111 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Interferon-Gamma Release Assays (IGRAs) (2020-2028) ($MN)
112 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Smear Microscopy (2020-2028) ($MN)
113 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Serological Antibody-Based Tests (2020-2028) ($MN)
114 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Culture (2020-2028) ($MN)
115 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Identification or Speciation Tests (2020-2028) ($MN)
116 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Nucleic Acid Amplification Tests (NAATs) (2020-2028) ($MN)
117 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Phenotypic Drug Susceptibility Tests (2020-2028) ($MN)
118 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Adenosine Deaminase (ADA) Test (2020-2028) ($MN)
119 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Type (2020-2028) ($MN)
120 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Sputum Smear Microscopy (2020-2028) ($MN)
121 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2020-2028) ($MN)
122 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Culture-based Diagnostics (2020-2028) ($MN)
123 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Other Types (2020-2028) ($MN)
124 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By End User (2020-2028) ($MN)
125 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Diagnostic Laboratories (2020-2028) ($MN)
126 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Hospitals (2020-2028) ($MN)
127 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Public (2020-2028) ($MN)
128 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Private (2020-2028) ($MN)
129 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Clinics (2020-2028) ($MN)
130 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Reference Laboratories (2020-2028) ($MN)
131 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Research Institutes and Academics (2020-2028) ($MN)
132 Asia Pacific Tuberculosis (TB) Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
133 South America Tuberculosis (TB) Diagnostics Market Outlook, By Country (2020-2028) ($MN)
134 South America Tuberculosis (TB) Diagnostics Market Outlook, By Product Types (2020-2028) ($MN)
135 South America Tuberculosis (TB) Diagnostics Market Outlook, By Detection of Latent Infection (2020-2028) ($MN)
136 South America Tuberculosis (TB) Diagnostics Market Outlook, By Cytokine Detection Assay (2020-2028) ($MN)
137 South America Tuberculosis (TB) Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2020-2028) ($MN)
138 South America Tuberculosis (TB) Diagnostics Market Outlook, By Nucleic Acid Testing (2020-2028) ($MN)
139 South America Tuberculosis (TB) Diagnostics Market Outlook, By Detection of Drug Resistance (2020-2028) ($MN)
140 South America Tuberculosis (TB) Diagnostics Market Outlook, By Radiographic Method (2020-2028) ($MN)
141 South America Tuberculosis (TB) Diagnostics Market Outlook, By Other Products (2020-2028) ($MN)
142 South America Tuberculosis (TB) Diagnostics Market Outlook, By Test Type (2020-2028) ($MN)
143 South America Tuberculosis (TB) Diagnostics Market Outlook, By Tuberculin Skin Tests (2020-2028) ($MN)
144 South America Tuberculosis (TB) Diagnostics Market Outlook, By Interferon-Gamma Release Assays (IGRAs) (2020-2028) ($MN)
145 South America Tuberculosis (TB) Diagnostics Market Outlook, By Smear Microscopy (2020-2028) ($MN)
146 South America Tuberculosis (TB) Diagnostics Market Outlook, By Serological Antibody-Based Tests (2020-2028) ($MN)
147 South America Tuberculosis (TB) Diagnostics Market Outlook, By Culture (2020-2028) ($MN)
148 South America Tuberculosis (TB) Diagnostics Market Outlook, By Identification or Speciation Tests (2020-2028) ($MN)
149 South America Tuberculosis (TB) Diagnostics Market Outlook, By Nucleic Acid Amplification Tests (NAATs) (2020-2028) ($MN)
150 South America Tuberculosis (TB) Diagnostics Market Outlook, By Phenotypic Drug Susceptibility Tests (2020-2028) ($MN)
151 South America Tuberculosis (TB) Diagnostics Market Outlook, By Adenosine Deaminase (ADA) Test (2020-2028) ($MN)
152 South America Tuberculosis (TB) Diagnostics Market Outlook, By Type (2020-2028) ($MN)
153 South America Tuberculosis (TB) Diagnostics Market Outlook, By Sputum Smear Microscopy (2020-2028) ($MN)
154 South America Tuberculosis (TB) Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2020-2028) ($MN)
155 South America Tuberculosis (TB) Diagnostics Market Outlook, By Culture-based Diagnostics (2020-2028) ($MN)
156 South America Tuberculosis (TB) Diagnostics Market Outlook, By Other Types (2020-2028) ($MN)
157 South America Tuberculosis (TB) Diagnostics Market Outlook, By End User (2020-2028) ($MN)
158 South America Tuberculosis (TB) Diagnostics Market Outlook, By Diagnostic Laboratories (2020-2028) ($MN)
159 South America Tuberculosis (TB) Diagnostics Market Outlook, By Hospitals (2020-2028) ($MN)
160 South America Tuberculosis (TB) Diagnostics Market Outlook, By Public (2020-2028) ($MN)
161 South America Tuberculosis (TB) Diagnostics Market Outlook, By Private (2020-2028) ($MN)
162 South America Tuberculosis (TB) Diagnostics Market Outlook, By Clinics (2020-2028) ($MN)
163 South America Tuberculosis (TB) Diagnostics Market Outlook, By Reference Laboratories (2020-2028) ($MN)
164 South America Tuberculosis (TB) Diagnostics Market Outlook, By Research Institutes and Academics (2020-2028) ($MN)
165 South America Tuberculosis (TB) Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
166 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Country (2020-2028) ($MN)
167 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Product Types (2020-2028) ($MN)
168 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Detection of Latent Infection (2020-2028) ($MN)
169 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Cytokine Detection Assay (2020-2028) ($MN)
170 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2020-2028) ($MN)
171 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Nucleic Acid Testing (2020-2028) ($MN)
172 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Detection of Drug Resistance (2020-2028) ($MN)
173 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Radiographic Method (2020-2028) ($MN)
174 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Other Products (2020-2028) ($MN)
175 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Test Type (2020-2028) ($MN)
176 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Tuberculin Skin Tests (2020-2028) ($MN)
177 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Interferon-Gamma Release Assays (IGRAs) (2020-2028) ($MN)
178 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Smear Microscopy (2020-2028) ($MN)
179 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Serological Antibody-Based Tests (2020-2028) ($MN)
180 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Culture (2020-2028) ($MN)
181 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Identification or Speciation Tests (2020-2028) ($MN)
182 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Nucleic Acid Amplification Tests (NAATs) (2020-2028) ($MN)
183 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Phenotypic Drug Susceptibility Tests (2020-2028) ($MN)
184 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Adenosine Deaminase (ADA) Test (2020-2028) ($MN)
185 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Type (2020-2028) ($MN)
186 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Sputum Smear Microscopy (2020-2028) ($MN)
187 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2020-2028) ($MN)
188 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Culture-based Diagnostics (2020-2028) ($MN)
189 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Other Types (2020-2028) ($MN)
190 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By End User (2020-2028) ($MN)
191 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Diagnostic Laboratories (2020-2028) ($MN)
192 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Hospitals (2020-2028) ($MN)
193 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Public (2020-2028) ($MN)
194 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Private (2020-2028) ($MN)
195 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Clinics (2020-2028) ($MN)
196 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Reference Laboratories (2020-2028) ($MN)
197 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Research Institutes and Academics (2020-2028) ($MN)
198 Middle East & Africa Tuberculosis (TB) Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.